Literature DB >> 25273827

Why is the General Ophthalmic Services (GOS) Contract that underpins primary eye care in the U.K. contrary to the public health interest?

D Shickle1, C J Davey1, S V Slade1.   

Abstract

The model for delivery of primary eye care in Europe varies from country to country with differing reliance on ophthalmologists, optometrists and dispensing opticians. Comparative analysis of models has tended to focus on interprofessional working arrangements, training and regulatory issues, rather than on whether a particular model is effective for delivering public health goals for that country. National Health Service (NHS) primary eye care services in the UK are predominantly provided under a General Ophthalmic Services (GOS) Contract between the NHS and practice owners (Contractors). Over two-thirds of sight tests conducted in England, Wales and Northern Ireland and all in Scotland are performed under a GOS Contract, however many people entitled to a GOS sight test do not take up their entitlement. The fee paid for sight tests conducted under a GOS Contract in England, Wales and Northern Ireland does not cover the full cost of conducting the examination. The shortfall must be made up through profits of sale of optical appliances but this business model can be a deterrent to establishing practices within socioeconomically deprived communities, and can also be a barrier to uptake of sight tests, even though many people are entitled to a NHS optical voucher towards the cost of spectacles or contact lenses. This paper critiques the GOS Contracts within the UK. We argue that aspects of the way the GOS Contract is implemented are contrary to the public health interest and that different approaches are needed to address eye health inequalities and to reduce preventable sight loss. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Public health

Mesh:

Year:  2014        PMID: 25273827     DOI: 10.1136/bjophthalmol-2014-305345

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  A Comparison of Spectacles Purchased Online and in UK Optometry Practice.

Authors:  Alison J Alderson; Alison Green; David Whitaker; Andrew J Scally; David B Elliott
Journal:  Optom Vis Sci       Date:  2016-10       Impact factor: 1.973

2.  Geographical inequalities in uptake of NHS funded eye examinations: Poisson modelling of small-area data for Essex, UK.

Authors:  Darren Shickle; Tracey M Farragher; Chris J Davey; Sarah V Slade; James Syrett
Journal:  J Public Health (Oxf)       Date:  2018-06-01       Impact factor: 2.341

3.  Findings from an opt-in eye examination service in English special schools. Is vision screening effective for this population?

Authors:  Lisa A Donaldson; Marek Karas; Donna O'Brien; J Margaret Woodhouse
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

4.  Shared Care for Patients with Diabetes at Risk of Retinopathy: A Feasibility Trial.

Authors:  Ranjana Mathur; Dirk F de Korne; Tien Yin Wong; Donald Tan Tiang Hwee; Peggy P Chiang; Edmund Wong; Bibhas Chakraborty; Ecosse L Lamoureux
Journal:  Int J Integr Care       Date:  2019-09-18       Impact factor: 5.120

5.  Hearing and vision care provided to older people residing in care homes: a cross-sectional survey of care home staff.

Authors:  Wendy Andrusjak; Ana Barbosa; Gail Mountain
Journal:  BMC Geriatr       Date:  2021-01-08       Impact factor: 3.921

6.  A prospective evaluation of the clinical safety and effectiveness of a COVID-19 Urgent Eyecare Service across five areas in England.

Authors:  Alexander G Swystun; Christopher J Davey
Journal:  Ophthalmic Physiol Opt       Date:  2021-11-10       Impact factor: 3.117

7.  Optometry independent prescribing during COVID lockdown in Wales.

Authors:  Paul Cottrell; Rachel North; Nik Sheen; Barbara Ryan
Journal:  Ophthalmic Physiol Opt       Date:  2022-08-12       Impact factor: 3.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.